Mr. Speaker, I was happy to see that the auditor general himself observed that the Patented Medicine Prices Review Board, has been, as he put it, a constraining influence on the price of patented medicines in Canada. That is a good thing.
As to recommendations for change, the member may know that the board itself is in the middle of public discussions and consultations about changes in its mandate and the way it does business.
We will be happy to look at the auditor general's observations as part of that. I will make sure that the board and its chair take them carefully into account.